

Patterns of Care for Stage II Colon Cancer by Lymph Node Harvest in Kentucky Madison Petersen, Bert Little, PhD, and C. Tyler Ellis, MD, MSCR Department of Pharmacology and Toxicology, School of Public Health and Information Sciences, and School of Medicine, University of Louisville

Introduction

• 34 colon cancer cases/100,000 individuals in Kentucy.¹

OF

- Certain factors affect treatment & overall survival.
- Stage based on depth of tumor invasion, lymph nodes (LN) involved, & metastasis.²
- Standard of care: harvest ≥12 LN at surgery.
- If LN positive, recommend adjuvant chemotherapy to reduce recurrence.
- <12 LN impact accurate staging & possible survival.
- Clinical conundrum: Should individuals with stage II colon cancer with <12LN harvest receive chemotherapy?

Objectives and Hypothesis

We hypothesize that guideline concordant lymph node harvest is **not** associated with chemotherapy utilization & overall survival.

Methods

- Kentucky Cancer Registry (KCR) used to identify all stage II colon cancer cases in Kentucky residents from 1995 - 2018.
- KCR is a premier cancer & population-based registry.
- Patient & tumor factors were analyzed.
- Univariate analyses performed using Chi-squared tests.
- Survival analyses performed using: Kaplan-Meier & Cox Proportional-Hazards models.
- Study was exempt by UofL IRB.


Stage II Colon Cancer < 12 Lymph Nodes Surgery Surgery plus Chemotheran Time (Months) Hazard Ratios for Chemotherapy Utilization Mucinous vs. Non-Mucinous T4 vs. non-T4 Tumor ≥12 LN vs. < 12 LN


Poor/Undifferentiated vs. Well diff.

Hazard models controlled for age, race, year of diagnosis, tumor grade, histology, T-status, lymph node harvest.

Results

- 9,856 total stage II cancer cases: 82% (n=8,056) surgery-only & 18% (n=1,800) surgery plus chemotherapy. Lymph node Harvest: 37% <12 LN & 63% ≥12LN total. Increase ≥12LN Harvest over time: 33% during period from 1995-1999 vs. 44% during 2015 – 2018, p-value < 0.01
- Similar rates of chemotherapy utilization over the study period. Reduced rates of chemotherapy in the elderly population: Age 70-79 years 32% surgery-only vs. 22% surgery plus chemotherapy, p-value 0.01.
- Mucinous vs. non-mucinous cancers- similar rates of chemotherapy utilization 20% vs. 18%, p-value 0.08. Poorly/undifferentiated tumors: 14% surgery-only vs. 19% surgery plus chemotherapy, p-value < 0.01. T4 tumors: 8% surgery vs. 18% surgery plus chemotherapy, p-value < 0.01.





Conclusions

- Low rates of recommended LN harvest with mild improvements over time.
- Age & T4-status were the only independent predictors of chemotherapy utilization.
- Improved survival with chemotherapy on univariate analysis, however, other factors nullified survival benefit on multivariate analysis.
- Limitations: other high-risk factors not included: margin status, tumor budding, perforation, obstruction, perineural invasion (PNI), high microsatellite instability (MSI-H), and lymphovasular invasion (LVI).

Significance and Future Directions

- LN harvest will continue to be tracked as marker of quality; however, other factors may affect the decision to utilize chemotherapy for stage II colon cancer.
- Analyze database with other high-risk factors.
- Evaluate the role of geographic location with chemotherapy utilization.

Acknowledgements

- Research supported by the NCI R25 University of Louisville Cancer Education Program NIH/NCI (R25-CA134283)
- Kentucky Cancer Registry collecting, managing, & making this data available for research.

References

1. Kentucky Cancer Registry. (2020, July 22). Age-Adjusted Invasive Cancer Incidence Rates in Kentucky. https://www.kcr.uky.edu/ 2. Scott R. Steele, MD, Tracy L. Hull, MD, Thomas E. Read, MD, Theodore J. Saclarides, MD, Anthony J. Senagore, MD, & Charles B. Whitlow, MD (Eds.). (2016). The ASCRS Textbook of Colon and Rectal Surgery (Third Edition). Springer International Publishing.